NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences got a double-digit boost today after the company announced that it had placed a Helicos Genetic Analysis System at the Ontario Institute for Cancer Research.
In mid-morning trade on the Nasdaq exchange on Thursday, the company's shares were up 40 percent to $1.40.
The instrument placement was the latest in a string of such agreements that the company has announced in recent weeks, including the sale of an instrument to an undisclosed biotechnology company and another placement at Massachusetts General Cancer Center.
Helicos President Steve Lombardi told GenomeWeb Daily News sister publication In Sequence earlier this week that there are now seven instruments outside of the company, including four placements at research institutes and three ordered by customers.